Thalidomide at 100 mg Shows Benefits as Maintenance Therapy in Multiple Myeloma Patients in Trial
A maintenance treatment with thalidomide at 100 mg a day was safe and seen to delay disease progression by more than three years in multiple myeloma…
News
Donation Will Establish Center for Multiple Myeloma Research in UK
Thanks to a £10 million donation (about $13,000,000), Imperial College London will establish a center for multiple myeloma research at the institution’s Hammersmith…
Measuring Blood Vessel Activity May Predict Multiple Myeloma Prognosis
A panel of blood markers that identifies tumors with more active blood vessels may help stratify multiple myeloma patients according to their risk, a study found.
Single-cell Profiling in Multiple Myeloma May Improve Diagnosis, Treatment, Study Suggests
Analysis of thousands of individual cells in multiple myeloma patients allows for a much more precise diagnosis — distinguishing asymptomatic, early-stage patients from those…
clonoSEQ Assay Now Covered by Medicare for Multiple Myeloma and Acute Lymphoblastic Leukemia
The clonoSEQ Assay — a test that detects cancer cells present in very small numbers in a patient’s bone marrow — will now be covered…
FDA Asked to OK Darzalex as Combo Therapy for Newly Diagnosed Group of Multiple Myeloma Patients
Janssen Biotech has asked that the U.S. Food and Drug Administration to expand the label for Darzalex (daratumumab) to include its use, in…
Recruitment Begins in Phase 1 Trial of C-CAR088 for Multiple Myeloma
A Phase 1 trial in China is recruiting multiple myeloma patients who failed prior treatments to study Cellular Biomedicine…
CLR 131 Significantly Extends Survival of Heavily Treated Multiple Myeloma Patients in Phase 1 Trial
Heavily treated multiple myeloma patients included in the first four dosing groups of Cellectar Biosciences’ Phase 1 trial lived for a median of 22 months…
Ayala Partnering with Novartis on Investigational AL102 for Treatment of Multiple Myeloma
In a new agreement, Ayala Pharmaceuticals will work with Novartis on the development and commercialization of AL102, an investigational treatment for…
Revlimid Maintenance Extends Survival Without Disease Worsening in Myeloma Patients, Phase 3 Trial Shows
Long-term maintenance treatment with Revlimid (lenalidomide) significantly improves the length of time multiple myeloma patients live without disease worsening after their first-line therapy…
